Genetic variants of NQO1 gene increase bladder cancer risk in Indian population and meta-analysis

Tumor Biology

Volumn 35, Issue 7, 2014, Pages 6415-6423

  Mandal, Raju K ^a   Dubey, Sandhya ^a   Panda, Aditya K ^b   Mittal, Rama D ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^b CENTRAL UNIVERSITY OF JHARKHAND   (India)

Author keywords

Bacillus Calmette Guerin; Bladder cancer; Meta analysis; NQO1 polymorphism

Indexed keywords

REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ADULT; ALLELE; ARTICLE; BLADDER CANCER; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; ETHNICITY; EXON; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; INDIAN; MAJOR CLINICAL STUDY; MALE; NQO1 GENE; POLYMERASE CHAIN REACTION; POPULATION GENETICS; PRIMARY PREVENTION; PRIORITY JOURNAL; PUBLISHING; RECURRENCE RISK; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SYSTEMATIC REVIEW; TUMOR GROWTH;

ASIAN CONTINENTAL ANCESTRY GROUP; EXONS; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NAD(P)H DEHYDROGENASE (QUINONE); NEOPLASM RECURRENCE, LOCAL; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SMOKING; URINARY BLADDER NEOPLASMS;

EID: 84904990875     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-1869-1     Document Type: Article

References (34)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. Sinha R, Anderson DE, McDonald SS, Greenwald P. Cancer risk and diet in India. J Postgrad Med. 2003;49:222-8. (Pubitemid 37493414)
3. Cohen SM, Shirai T, Steineck G. Epidemiology and etiology of premalignant and malignant urothelial changes. Scand J Urol Nephrol Suppl. 2000;205:105-15. (Pubitemid 32056470)
4. Schlager JJ, Powis G. Cytosolic NAD(P)H:(quinoneacceptor) oxidoreductase in human normal and tumor tissue: effects of cigarette smoking and alcohol. Int J Cancer. 1990;45:403-9. (Pubitemid 20087182)
5. Choudry GA, Stewart PA, Double JA, Krul MR, Naylor B, Flannigan GM, et al. A novel strategy for NQO1 (NAD(P)H:quinine oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9. Br J Cancer. 2001;85:1137-46. (Pubitemid 33052312)
6. Traver RD, Siegel D, Beall HD, Phillips RM, Gibson NW, Franklin WA, et al. Characterization of a polymorphismin NAD(P)H: quinone oxidoreductase (DT-diaphorase). Br J Cancer. 1997;75:69-75. (Pubitemid 27007275)
7. Schulz WA, Krummeck A, Rösinger I, Eickelmann P, Neuhaus C, Ebert T, et al. Increased frequency of a null-allele for NAD(P)H: quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics. 1997;7:235-9. (Pubitemid 27290637)
8. Colombel M, Soloway M, Akaza H. Epidemiology, staging, grading and risk stratification of bladder cancer. Eur Urol Suppl. 2008;7:618-26.
9. Sanyal S, Festa F, Sakano S, Zhang Z, Steineck G, Norming U, et al. Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis. 2004;25:729-34. (Pubitemid 38618524)
10. Malik MA, Zargar SA, Mittal B. Role of NQO1 609C>Tand NQO2-3423G>A polymorphisms in susceptibility to gastric cancer in Kashmir valley. DNA Cell Biol. 2011;30:297-303.
11. Egger M, Davey Smith G, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test.BMJ. 1997;315:629-34. (Pubitemid 27387172)
12. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-48.
13. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88. (Pubitemid 17189972)
14. Johns LE, Houlston RS. N-acetyl transferase-2 and bladder cancer risk: a meta-analysis. Environ Mol Mutagen. 2000;36:221-7.
15. Joseph P, Jaiswal AK. NAD(P)H:quinone oxidoreductase1 (DT diaphorase) specifically prevents the formation of benzo[a]pyrene quinone-DNA adducts generated by cytochrome P4501A1 and P450 reductase. Proc Natl Acad Sci U S A. 1994;91:8413-7. (Pubitemid 24273674)
16. Iskander K, Paquet M, Brayton C, Jaiswal AK. Deficiency of NRH: quinone oxidoreductase 2 increases susceptibility to 7,12-dimethylbenz(a)anthracene and benzo(a)pyrene-induced skin carcinogenesis. Cancer Res. 2004;64:5925-8. (Pubitemid 39129385)
17. Misra V, Grondin A, Klamut HJ, Rauth AM. Assessment of the relationship between genotypic status of a DT-diaphorase point mutation and enzymatic activity. Br J Cancer. 2000;83:998-1002.
18. Huang ZM, Chen HA, Chiang YT, Shen CH, Tung MC, Juang GD (2013) Association of polymorphisms in iNOS and NQO1 with bladder cancer risk in cigarette smokers. J Chin Med Assoc Dec 4
19. Pandith AA, Khan NP, Shah ZA, Shah AM, Wani SM, Siddiqi MA. Association of bladder cancer risk with an NAD(P)H: quinone oxidoreductase polymorphism in an ethnic Kashmiri population. Biochem Genet. 2011;49:417-26.
20. Park SJ, Zhao H, Spitz MR, Grossman HB, Wu X. An association between NQO1 genetic polymorphism and risk of bladder cancer. Mutat Res. 2003;536:131-7. (Pubitemid 36411663)
21. Peng XE, Jiang YY, Shi XS, Hu ZJ. NQO1 609C>T polymorphism interaction with tobacco smoking and alcohol drinking increases colorectal cancer risk in a Chinese population. Gene. 2013;521:105-10.
22. Mandal RK, Nissar K, Mittal RD. Genetic variants in metabolizing genes NQO1, NQO2, MTHFR and risk of prostate cancer: a study from North India. Mol Biol Rep. 2012;39:11145-52.
23. Hu X, Zhang Z, Ma D, Huettner PC, Massad LS, Nguyen L, et al. TP53, MDM2, NQO1, and susceptibility to cervical cancer. Cancer Epidemiol Biomarkers Prev. 2010;19:755-61.
24. Yuan W, Xu L, Chen W, Wang L, Fu Z, Pang D, et al. Evidence on the association between NQO1 Pro187Ser polymorphism and breast cancer risk in the current studies: a meta-analysis. Breast Cancer Res Treat. 2011;125:467-72.
25. Chen S, Knox R, Lewis AD, Friedlos F, Workman P, Deng PS, et al. Catalytic properties of NAD(P)H:quinone acceptor oxidoreductase: study involving mouse, rat, human, andmouse-rat chimeric enzymes. Mol Pharmacol. 1995;47:934-9.
26. Siegel D, McGuinness SM, Winski SL, Ross D. Genotypephenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics. 1999;9:113-21. (Pubitemid 29176730)
27. Zhu CL, Huang Q, Liu CH, Lin XS, Xie F, Shao F. NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T gene polymorphism association with digestive tract cancer: a meta-analysis. Asian Pac J Cancer Prev. 2013;14:2349-54.
28. Han FF, Guo CL, Gong LL, Jin Z, Liu LH. Effects of the NQO1 609C>T polymorphism on leukemia susceptibility: Evidence from a meta-analysis. Asian Pac J Cancer Prev. 2013;14:5311-6.
29. Wang YH, Lee YH, Tseng PT, Shen CH, Chiou HY. Human NAD(P)H:quinone oxidoreductase 1 (NQO1) and sulfotransferase 1A1 (SULT1A1) polymorphisms and urothelial cancer risk in Taiwan. J Cancer Res Clin Oncol. 2008;134:203-9. (Pubitemid 350234065)
30. Terry PD, Umbach DM, Taylor JA. No association between SOD2 or NQO1 genotypes and risk of bladder cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:753-4. (Pubitemid 40489229)
31. Broberg K, Björk J, Paulsson K, Höglund M, Albin M. Constitutional short telomeres are strong genetic susceptibility markers for bladder cancer. Carcinogenesis. 2005;26:1263-71. (Pubitemid 41417904)
32. Hung RJ, Boffetta P, Brennan P, Malaveille C, Gelatti U, Placidi D, et al. Genetic polymorphisms of MPO, COMT, MnSOD, NQO1, interactions with environmental exposures and bladder cancer risk. Carcinogenesis. 2004;25:973-8. (Pubitemid 38886083)
33. Moore LE, Wiencke JK, Bates MN, Zheng S, Rey OA, Smith AH. Investigation of genetic polymorphisms and smoking in a bladder cancer case-control study in Argentina. Cancer Lett. 2004;211:199-207. (Pubitemid 38824633)
34. Choi JY, Lee KM, Cho SH, Kim SW, Choi HY, Lee SY, et al. CYP2E1 and NQO1 genotypes, smoking and bladder cancer. Pharmacogenetics. 2003;13:349-55.